



TRENDS-in-MEDICINE

BULLETIN:

AMERICAN HEART ASSOCIATION – PREVIEW

September 5, 2016
by Lynne Peterson

The American Heart Association meeting takes place in New Orleans from November 12-16, 2016, and there are a number of interesting studies that will be presented. The key ones are listed below, by date and company, where applicable. Perhaps this will help in your planning/preparation for the meeting.

Sunday 11/13

3:45 – 5:00 pm Late Breakers

- **AstraZeneca's Brilinta (ticagrelor)** – EUCLID trial of ticagrelor + clopidogrel in peripheral artery disease (PAD)
- **Pfizer's Celebrex (celecoxib)** – PRECISION, a cardiovascular outcomes trial of this Cox-2 inhibitor vs. ibuprofen or naproxen
- A study on the effect of blood pressure and cholesterol lowering on *cognition*

Monday 11/14

10:45 am – 12 noon Late Breakers

- **FFR – FUTURE trial**, a French real-world comparison of fractional flow reserve (FFR)-guided management vs. conventional management in multi-vessel coronary artery disease (CAD) patients
- **Johnson & Johnson's Xarelto (rivaroxaban)** – PIONEER AF-PCI trial, an open-label, multicenter study of this Factor Xa inhibitor vs. warfarin in atrial fibrillation patients having PCI
- **TAVR** – 1-year results from the German Aortic Valve Registry (GARY) comparing transcatheter aortic valve replacement (TAVR) in intermediate-risk patients to surgical aortic valve replacement (SAVR)

3:45 – 5:00 pm Special reports on cell therapy

- **PACE trial** – Study of aldehyde dehydrogenase bright (ALDHbr) bone marrow cells given by intramuscular injections into the calf and lower thigh muscles to treat peripheral artery disease – sponsored and run by the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH)
- **POSEIDON-DCM trial** – Study of allogeneic vs. autologous mesenchymal stem cells for non-ischemic dilated cardiomyopathy, sponsored by NHLBI
- **TIME trial** – 2-year clinical and MRI follow-up of role of microvascular obstruction

Trends-in-Medicine ■ 2731 N.E. Pinecrest Lakes Blvd ■ Jensen Beach FL 34957
772-334-7409 / 800-589-5018 ■ Fax 772-334-0856 ■ www.trends-in-medicine.com

Trends-in-Medicine has no financial connections with any pharmaceutical or medical device company. The information and opinions expressed have been compiled or arrived at from sources believed to be reliable and in good faith, but no liability is assumed for information contained in this newsletter. Copyright ©2016.

This document may not be reproduced without written permission of the publisher.

Tuesday 11/15**10:45 am – 12 noon Late Breakers**

- **Amgen's Repatha (evolocumab)** – GLAGOV trial, an IVUS study of the effects of this PCSK9 inhibitor on coronary atherosclerosis
- **CSL Behring's CSL-112** – AEGIS-I trial of the effect of this apoA-1 milano RNAi inhibitor on ischemic syndromes after acute myocardial infarction
- **Ionis Pharmaceuticals/Akcea Therapeutics' Ionis-angptl3-IRx** – The results of this antisense inhibitor of angiopoietin-like protein 3 (angptl3) in healthy volunteers with elevated triglycerides and in patients with familial hypercholesterolemia
- **The Medicines Company's ALN-PCSSc (MDCO-216, apoA-1 milano)**
 - ORION-1 trial – 90-day results from a Phase II trial of this RNAi inhibitor in hypercholesterolemia
 - MILANO-PILOT – results of this double-blind trial of change in atheroma volume at Day 36 in ACS patients

10:45 am – 12 noon High impact registries and trials

- **Boston Scientific's Watchman** – initial U.S. postmarketing experience with this left atrial appendage closure device in stroke prevention in atrial fibrillation patients
- **Boehringer Ingelheim's Praxbind (idarucizumab)** – RE-VERSE-AD trial of this reversal agent for Pradaxa (dabigatran)

3:45 – 5:00 pm Special reports

- Incidence of AMI in familial hypercholesterolemia patients in Norway 2001-2009
- CETP inhibitors – loss-of-function variant is associated with altered lipid metabolism but not with cardiovascular disease in Chinese study
- PCI: MACE outcomes in real-world setting with use of CYP2C19 genotype-guided antiplatelet therapy

Wednesday 11/16**10:45 am – 12 noon Late Breakers**

- **Corvia Medical's transcatheter interatrial shunt** – REDUCE-LAP-HF trial, 1-year results in patients with heart failure with preserved ejection fraction (HFpEF) or mildly reduced ejection fraction
- **Pfizer's Aldactone (spironolactone)** – ATHENA-HF trial of targeted neurohormonal therapy with natriuresis therapy in heart failure patients
- Over-the-counter oral iron – IRONOUT-HF, an investigator-initiated study of oral iron vs. placebo in heart failure patients
- **American Regent's Injectafer (ferric carboxymaltose)** – EFFECT-HF trial of this injectable iron's effect on exercise capacity in heart failure patients with iron deficiency
- **St. Jude Medical's HeartMate 3** – MOMENTUM-3 trial – 6-month results with this left ventricular assist device (LVAD) vs. HeartMate 2

